FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies

BACKGROUND: FIGHT‐102 was a phase 1, dose‐escalation, dose‐expansion study of pemigatinib in Japanese patients with advanced solid tumors. Here, we report safety, tolerability, and preliminary efficacy of pemigatinib from FIGHT‐102. METHODS: Patients (≥20 years old) self‐administered oral pemigatini...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Yutaka, Kuboki, Yasutoshi, Furukawa, Masayuki, Mizuno, Nobumasa, Hara, Hiroki, Ioka, Tatsuya, Ueno, Makoto, Takahashi, Yasuo, Takahashi, Shunji, Takeuchi, Shinji, Lihou, Christine, Ji, Tao, Tian, Chenwei, Shimizu, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225205/
https://www.ncbi.nlm.nih.gov/pubmed/37000035
http://dx.doi.org/10.1002/cam4.5798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225205/
https://www.ncbi.nlm.nih.gov/pubmed/37000035
http://dx.doi.org/10.1002/cam4.5798

Ejemplares similares